{
    "nctId": "NCT05346107",
    "briefTitle": "PLD-cyclophosphamide-Nab-P Continuously Combined With Dual HER2 Blockage for HER2-positive Breast Cancer",
    "officialTitle": "PLD Plus Cyclophosphamide Followed by Nab-paclitaxel (Nab-P) as Primary Chemotherapy Continuously Combined With Dual HER2 Blockage for HER2-positive Breast Cancer: A Single-arm Phase 2 Trial(Brecan Trial)",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Cancer, HER2-positive Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 100,
    "primaryOutcomeMeasure": "Rate of pathological complete response",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. HER2-positive breast cancer\n2. cT2-3/N0-1/M0\n3. aged18-80 years\n4. receiving neoadjuvant therapy\n5. ECOGPS score 0 or 1\n6. Able to understand the test requirements, willing and able to comply with the test and follow-up procedures\n7. Adequate organ function\n\nExclusion Criteria:\n\n1. cardiac, hepatic, renal, or psychiatric disease history\n2. History of other malignancy within the last 5 years, with the exception of adequately treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}